NASDAQ:CASI - EntreMed Stock Price, Price Target & More

$6.46 -0.26 (-3.87 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$6.46
Today's Range$6.4270 - $6.9072
52-Week Range$0.91 - $7.61
Volume589,347 shs
Average Volume540,620 shs
Market Capitalization$602.55 million
P/E Ratio-35.89
Dividend YieldN/A
Beta0.9

About EntreMed (NASDAQ:CASI)

EntreMed logoCASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. The company's late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. In addition, its pipeline includes 2ME2 (2-methoxyestradial), an orally active compound that has antiproliferative, antiangiogenic, and anti-inflammatory properties. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Receive CASI News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CASI
CUSIPN/A
Phone240-864-2600

Debt

Debt-to-Equity Ratio0.04%
Current Ratio8.66%
Quick Ratio8.66%

Price-To-Earnings

Trailing P/E Ratio-35.89
Forward P/E Ratio-29.36
P/E GrowthN/A

Sales & Book Value

Annual Sales$50,000.00
Price / Sales11,121.54
Cash FlowN/A
Price / CashN/A
Book Value$0.55 per share
Price / Book11.75

Profitability

EPS (Most Recent Fiscal Year)($0.18)
Net Income$-10,770,000.00
Net MarginsN/A
Return on Equity-47.68%
Return on Assets-36.47%

Miscellaneous

Employees51
Outstanding Shares86,080,000

How to Become a New Pot Stock Millionaire

EntreMed (NASDAQ:CASI) Frequently Asked Questions

What is EntreMed's stock symbol?

EntreMed trades on the NASDAQ under the ticker symbol "CASI."

How were EntreMed's earnings last quarter?

EntreMed, Inc. (NASDAQ:CASI) released its earnings results on Thursday, March, 29th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.06. View EntreMed's Earnings History.

What price target have analysts set for CASI?

2 equities research analysts have issued 1 year price targets for EntreMed's shares. Their forecasts range from $4.00 to $7.00. On average, they expect EntreMed's stock price to reach $5.50 in the next twelve months. View Analyst Ratings for EntreMed.

What are Wall Street analysts saying about EntreMed stock?

Here are some recent quotes from research analysts about EntreMed stock:
  • 1. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Acquisition of Sandoz Portfolio Could Lead to Commerical Launch in 12 Months; Reiterate Buy A transformative acquisition. On January 26, CASI announced the acquisition of an abbreviated new drug application (ANDA) portfolio from Sandoz, the generic drug division of Novartis (NVS; not rated), for $18M. The portfolio includes several essential medications such as Entecavir, Lisinopril, Methimazole, and Midodrine and covers a broad spectrum of drugs such as antivirals, anti-depressants, hypertension drugs, and anti-inflammatory drugs. In our view, the acquisition of these 25 approved and 4 pending ANDAs is a transformative event for the company. With the worldwide ANDA data exclusivity, CASI can now quickly become a commercial force in both China and the US." (1/29/2018)
  • 2. Maxim Group analysts commented, "CASI Pharmaceuticals reported 3Q17 with a net loss of $1.6M and ended the period with $21.6M in cash. The company completed an equity financing in October, raising $23.8M. Combined, we estimate CASI currently has $44M on the balance sheet, sufficient runway into 2020. Our model has been adjusted accordingly. As we had already factored in future capital raises, the net effect is our price target of $4 remains unchanged." (11/14/2017)

Are investors shorting EntreMed?

EntreMed saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 1,871,455 shares, an increase of 33.8% from the March 30th total of 1,399,161 shares. Based on an average daily trading volume, of 2,179,588 shares, the short-interest ratio is presently 0.9 days. Approximately 9.1% of the shares of the company are short sold.

Who are some of EntreMed's key competitors?

Who are EntreMed's key executives?

EntreMed's management team includes the folowing people:
  • Dr. Wei-Wu He Ph.D., Exec. Chairman (Age 53)
  • Dr. Ken Keyong Ren M.D., Ph.D., Chief Exec. Officer and Director (Age 59)
  • Ms. Sara B. Capitelli CPA, Principal Accounting Officer and Vice-Pres of Fin. (Age 52)
  • Ms. Cynthia Wong Hu J.D., Chief Operating Officer, Gen. Counsel and Sec. (Age 48)
  • Dr. James E. Goldschmidt Ph.D., VP of Bus. Devel.

Has EntreMed been receiving favorable news coverage?

Press coverage about CASI stock has trended positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. EntreMed earned a media sentiment score of 0.42 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 43.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of EntreMed?

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EntreMed's stock price today?

One share of CASI stock can currently be purchased for approximately $6.46.

How big of a company is EntreMed?

EntreMed has a market capitalization of $602.55 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-10,770,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. EntreMed employs 51 workers across the globe.

How can I contact EntreMed?

EntreMed's mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]


MarketBeat Community Rating for EntreMed (CASI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about EntreMed and other stocks. Vote "Outperform" if you believe CASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

EntreMed (NASDAQ:CASI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for EntreMed in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible downside of 14.86%. The high price target for CASI is $7.00 and the low price target for CASI is $4.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.50$4.25$4.50$3.00
Price Target Upside: 14.86% downside9.82% upside20.00% upside172.73% upside

EntreMed (NASDAQ:CASI) Consensus Price Target History

Price Target History for EntreMed (NASDAQ:CASI)

EntreMed (NASDAQ:CASI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018HC WainwrightReiterated RatingBuy$7.00HighView Rating Details
11/14/2017Maxim GroupSet Price TargetBuy$4.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

EntreMed (NASDAQ:CASI) Earnings History and Estimates Chart

Earnings by Quarter for EntreMed (NASDAQ:CASI)

EntreMed (NASDAQ:CASI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.22 EPS
Next Year EPS Consensus Estimate: $-0.16 EPS

EntreMed (NASDAQ CASI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018Q4($0.02)($0.08)$0.50 millionViewN/AView Earnings Details
11/14/2017Q3 2017($0.04)($0.03)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.03)($0.04)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.04)($0.0280)ViewN/AView Earnings Details
3/31/2017Q4 2016($0.07)($0.05)$0.50 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.08)($0.03)ViewN/AView Earnings Details
8/15/2016Q2($0.04)($0.08)ViewN/AView Earnings Details
5/13/2016Q1($0.05)($0.04)ViewN/AView Earnings Details
3/28/2016Q415($0.03)($0.05)$0.03 millionViewN/AView Earnings Details
11/13/2015Q315($0.0650)($0.05)$0.10 millionViewN/AView Earnings Details
8/14/2015Q215($0.0550)($0.06)$0.27 million$0.02 millionViewN/AView Earnings Details
5/15/2015Q1 2015($0.06)$0.02 millionViewN/AView Earnings Details
3/27/2015Q4 2014($0.05)$0.02 millionViewN/AView Earnings Details
11/14/2014Q314($0.07)ViewN/AView Earnings Details
8/14/2014Q214($0.06)ViewN/AView Earnings Details
5/15/2014Q114($0.05)($0.05)ViewN/AView Earnings Details
3/21/2014Q413($0.05)$0.6693 millionViewN/AView Earnings Details
11/13/2013Q3($0.05)($0.05)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.07)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.02)$1.93 million$0.6693 millionViewN/AView Earnings Details
11/14/2012Q312($0.05)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.55)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.23)ViewN/AView Earnings Details
3/9/2012Q4 2011$0.06ViewN/AView Earnings Details
11/14/2011Q3 2011($0.13)ViewN/AView Earnings Details
8/15/2011Q2 2011($0.17)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.25)ViewN/AView Earnings Details
3/30/2011Q4 2010$0.07ViewN/AView Earnings Details
11/12/2010Q3 2010($0.24)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.26)ViewN/AView Earnings Details
5/18/2010Q1 2010($0.25)ViewN/AView Earnings Details
3/29/2010Q4 2009($0.29)ViewN/AView Earnings Details
11/16/2009Q3 2009$0.01ViewN/AView Earnings Details
8/6/2009Q2 2009($0.40)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.44)ViewN/AView Earnings Details
3/12/2009Q4 2008($0.35)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.43)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.98)ViewN/AView Earnings Details
5/2/2008Q1 2008($1.08)ViewN/AView Earnings Details
3/6/2008Q4 2007($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

EntreMed (NASDAQ:CASI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

EntreMed (NASDAQ CASI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.66%
Institutional Ownership Percentage: 4.53%
Insider Trading History for EntreMed (NASDAQ:CASI)
Institutional Ownership by Quarter for EntreMed (NASDAQ:CASI)

EntreMed (NASDAQ CASI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/21/2018China Growth Fund Idg-Accel IIMajor ShareholderBuy3,086,418$3.19$9,845,673.42View SEC Filing  
3/19/2018Wei-Wu HeDirectorBuy3,086,419$3.24$9,999,997.56847,527View SEC Filing  
12/22/2017Spectrum Pharmaceuticals IncMajor ShareholderBuy1,519,096$0.01$15,190.966,897,413View SEC Filing  
10/10/2017Wei-Wu HeDirectorBuy100,000$1.95$195,000.00View SEC Filing  
10/6/2017Wei-Wu HeDirectorBuy200,000$1.83$366,000.00View SEC Filing  
9/19/2017Wei-Wu HeDirectorBuy207,502$1.75$363,128.50513,525View SEC Filing  
9/18/2017Wei-Wu HeDirectorBuy173,500$1.75$303,625.00513,525View SEC Filing  
9/15/2017Wei-Wu HeDirectorBuy315,327$1.33$419,384.91212,323View SEC Filing  
10/28/2016Spectrum Pharmaceuticals IncMajor ShareholderBuy1,789,062$0.01$17,890.625,695,242View SEC Filing  
10/3/2016Wei-Wu HeDirectorBuy1,871,605$1.19$2,227,209.9524,698View SEC Filing  
6/24/2016Byte Ltd SparkleMajor ShareholderBuy3,753,855$1.19$4,467,087.45View SEC Filing  
3/7/2016China Growth Fund Idg-Accel IIMajor ShareholderBuy972,708$2.40$2,334,499.20View SEC Filing  
1/19/2016Cynthia W. HuCOOBuy16,800$0.72$12,096.0017,785View SEC Filing  
1/19/2016Ken RenCEOBuy15,000$0.73$10,950.0015,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

EntreMed (NASDAQ CASI) News Headlines

Source:
DateHeadline
Critical Review: EntreMed (CASI) and Seattle Genetics (SGEN)Critical Review: EntreMed (CASI) and Seattle Genetics (SGEN)
www.americanbankingnews.com - April 25 at 3:32 PM
-$0.07 EPS Expected for EntreMed, Inc. (CASI) This Quarter-$0.07 EPS Expected for EntreMed, Inc. (CASI) This Quarter
www.americanbankingnews.com - April 24 at 7:21 PM
Zacks: Brokerages Expect EntreMed, Inc. (CASI) to Announce -$0.02 EPSZacks: Brokerages Expect EntreMed, Inc. (CASI) to Announce -$0.02 EPS
www.americanbankingnews.com - April 7 at 7:10 PM
Here's Why CASI Pharmaceuticals Rose as Much as 23.4% TodayHere's Why CASI Pharmaceuticals Rose as Much as 23.4% Today
finance.yahoo.com - April 6 at 4:30 PM
CASI Pharmaceuticals Provides Update On EVOMELA®CASI Pharmaceuticals Provides Update On EVOMELA®
finance.yahoo.com - April 5 at 8:49 AM
HC Wainwright Analysts Give EntreMed (CASI) a $7.00 Price TargetHC Wainwright Analysts Give EntreMed (CASI) a $7.00 Price Target
www.americanbankingnews.com - April 4 at 10:28 AM
BidaskClub Upgrades EntreMed (CASI) to "Buy"BidaskClub Upgrades EntreMed (CASI) to "Buy"
www.americanbankingnews.com - April 4 at 9:31 AM
EntreMed (CASI) Rating Increased to Buy at ValuEngineEntreMed (CASI) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 7:01 PM
 Analysts Set $5.83 Price Target for EntreMed, Inc. (CASI) Analysts Set $5.83 Price Target for EntreMed, Inc. (CASI)
www.americanbankingnews.com - April 1 at 1:28 AM
EntreMed (CASI) Announces  Earnings ResultsEntreMed (CASI) Announces Earnings Results
www.americanbankingnews.com - March 30 at 7:54 AM
CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial ResultsCASI Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results
finance.yahoo.com - March 29 at 10:05 AM
EntreMed (CASI) Receives "Buy" Rating from HC WainwrightEntreMed (CASI) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - March 28 at 2:42 PM
Insider Buying: CASI Pharmaceuticals Inc (CASI) Major Shareholder Buys 3,086,418 Shares of StockInsider Buying: CASI Pharmaceuticals Inc (CASI) Major Shareholder Buys 3,086,418 Shares of Stock
www.americanbankingnews.com - March 23 at 4:32 PM
CASI Pharmaceuticals (CASI) Scheduled to Post Earnings on ThursdayCASI Pharmaceuticals (CASI) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 22 at 1:14 AM
Wei-Wu He Buys 3,086,419 Shares of CASI Pharmaceuticals Inc (CASI) StockWei-Wu He Buys 3,086,419 Shares of CASI Pharmaceuticals Inc (CASI) Stock
www.americanbankingnews.com - March 21 at 7:14 PM
CASI Pharmaceuticals (CASI) Stock Rating Upgraded by ValuEngineCASI Pharmaceuticals (CASI) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 21 at 12:50 AM
CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In China - PR Newswire (press release)CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In China - PR Newswire (press release)
www.prnewswire.com - March 20 at 4:11 PM
CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In ChinaCASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In China
finance.yahoo.com - March 20 at 9:52 AM
CASI Pharmaceuticals (CASI) Downgraded to "Sell" at ValuEngineCASI Pharmaceuticals (CASI) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - March 18 at 8:16 PM
Analyzing Mesoblast (MESO) and CASI Pharmaceuticals (CASI)Analyzing Mesoblast (MESO) and CASI Pharmaceuticals (CASI)
www.americanbankingnews.com - March 5 at 9:38 AM
CASI Pharmaceuticals Inc (CASI) Short Interest UpdateCASI Pharmaceuticals Inc (CASI) Short Interest Update
www.americanbankingnews.com - March 3 at 3:26 AM
BidaskClub Downgrades CASI Pharmaceuticals (CASI) to BuyBidaskClub Downgrades CASI Pharmaceuticals (CASI) to Buy
www.americanbankingnews.com - February 14 at 10:40 PM
BRIEF-CASI Pharma Board Approves Appointment Of Wei-Wu He As Executive ChairmanBRIEF-CASI Pharma Board Approves Appointment Of Wei-Wu He As Executive Chairman
www.reuters.com - February 9 at 5:33 PM
CASI Pharmaceuticals to Present at the BIO CEO & Investor ConferenceCASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
finance.yahoo.com - February 9 at 9:05 AM
Wired News – CASI Pharma Purchased abbreviated new drug applications Portfolio from SandozWired News – CASI Pharma Purchased abbreviated new drug applications Portfolio from Sandoz
finance.yahoo.com - January 30 at 9:23 AM
CASI Pharmaceuticals (CASI) Given "Buy" Rating at HC WainwrightCASI Pharmaceuticals (CASI) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - January 29 at 8:22 AM
CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz)CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz)
finance.yahoo.com - January 27 at 9:21 AM
FY2017 EPS Estimates for CASI Pharmaceuticals, Inc. (CASI) Increased by AnalystFY2017 EPS Estimates for CASI Pharmaceuticals, Inc. (CASI) Increased by Analyst
www.americanbankingnews.com - January 8 at 2:56 AM
Spectrum Pharmaceuticals Inc Buys 1,519,096 Shares of CASI Pharmaceuticals, Inc. (CASI) StockSpectrum Pharmaceuticals Inc Buys 1,519,096 Shares of CASI Pharmaceuticals, Inc. (CASI) Stock
www.americanbankingnews.com - December 22 at 6:14 PM
Free Research Reports on these Biotech Stocks -- Vericel, ZIOPHARM Oncology, Cerecor, and CASI Pharma - PR Newswire (press release)Free Research Reports on these Biotech Stocks -- Vericel, ZIOPHARM Oncology, Cerecor, and CASI Pharma - PR Newswire (press release)
www.prnewswire.com - December 19 at 4:58 PM
Mid-Morning Market Update: Markets Open Higher; VeriFone Issues Weak Outlook - NasdaqMid-Morning Market Update: Markets Open Higher; VeriFone Issues Weak Outlook - Nasdaq
www.nasdaq.com - December 13 at 5:09 PM
CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)
finance.yahoo.com - December 1 at 5:10 PM
 CASI Pharmaceuticals, Inc. (CASI) Given $3.50 Consensus Price Target by Brokerages CASI Pharmaceuticals, Inc. (CASI) Given $3.50 Consensus Price Target by Brokerages
www.americanbankingnews.com - November 23 at 1:28 PM
CASI Pharmaceuticals, Inc. (CASI) Posts Quarterly  Earnings Results, Beats Expectations By $0.01 EPSCASI Pharmaceuticals, Inc. (CASI) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 15 at 1:05 PM
CASI Pharmaceuticals Reports Third Quarter 2017 Financial ResultsCASI Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 5:27 PM
CASI Pharmaceuticals (CASI) Buy Rating Reiterated at Maxim GroupCASI Pharmaceuticals' (CASI) Buy Rating Reiterated at Maxim Group
www.americanbankingnews.com - November 14 at 4:40 PM
CASI Pharmaceuticals, Inc. (CASI) Scheduled to Post Quarterly Earnings on MondayCASI Pharmaceuticals, Inc. (CASI) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 5:22 AM
CASI Pharmaceuticals (CASI) vs. Brainstorm Cell Therapeutics (BCLI) Head to Head ComparisonCASI Pharmaceuticals (CASI) vs. Brainstorm Cell Therapeutics (BCLI) Head to Head Comparison
www.americanbankingnews.com - November 5 at 9:12 PM
-$0.04 EPS Expected for CASI Pharmaceuticals, Inc. (CASI) This Quarter-$0.04 EPS Expected for CASI Pharmaceuticals, Inc. (CASI) This Quarter
www.americanbankingnews.com - November 1 at 9:16 PM
Analyzing CASI Pharmaceuticals (CASI) and Adamas Pharmaceuticals (ADMS)Analyzing CASI Pharmaceuticals (CASI) and Adamas Pharmaceuticals (ADMS)
www.americanbankingnews.com - November 1 at 5:12 PM
CASI Pharmaceuticals, Capital Raise, Analysts Review, Product Development, and GuidanceCASI Pharmaceuticals, Capital Raise, Analysts Review, Product Development, and Guidance
finance.yahoo.com - October 31 at 6:07 PM
Reviewing CASI Pharmaceuticals (CASI) & The CompetitionReviewing CASI Pharmaceuticals (CASI) & The Competition
www.americanbankingnews.com - October 21 at 2:24 AM
CASI Pharma (CASI) Announces 7.95M Share Registed Direct Offering at $3/ShCASI Pharma (CASI) Announces 7.95M Share Registed Direct Offering at $3/Sh
www.streetinsider.com - October 14 at 4:43 PM
CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders - PR Newswire (press release)CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders - PR Newswire (press release)
www.prnewswire.com - October 14 at 3:37 AM
CASI Pharmaceuticals Reaches Analyst Target PriceCASI Pharmaceuticals Reaches Analyst Target Price
www.thestreet.com - October 13 at 5:37 PM
CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing ShareholdersCASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders
finance.yahoo.com - October 13 at 5:37 PM
Insider Buying: CASI Pharmaceuticals, Inc. (CASI) Director Purchases 100,000 Shares of StockInsider Buying: CASI Pharmaceuticals, Inc. (CASI) Director Purchases 100,000 Shares of Stock
www.americanbankingnews.com - October 11 at 7:50 PM
CASI Pharmaceuticals, Inc. (CASI) Director Acquires $366,000.00 in StockCASI Pharmaceuticals, Inc. (CASI) Director Acquires $366,000.00 in Stock
www.americanbankingnews.com - October 10 at 7:38 PM
Head-To-Head Review: CASI Pharmaceuticals (CASI) & Its RivalsHead-To-Head Review: CASI Pharmaceuticals (CASI) & Its Rivals
www.americanbankingnews.com - September 25 at 2:20 AM
CASI Pharmaceuticals, Inc. (CASI) Expected to Announce Earnings of -$0.04 Per ShareCASI Pharmaceuticals, Inc. (CASI) Expected to Announce Earnings of -$0.04 Per Share
www.americanbankingnews.com - September 25 at 2:16 AM

SEC Filings

EntreMed (NASDAQ:CASI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

EntreMed (NASDAQ:CASI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

EntreMed (NASDAQ CASI) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.